Carvedilol to Improve Cardiac Remodeling in Anthracycline-Exposed Childhood Cancer Survivors: Subgroup Analysis of COG ALTE1621.
作者信息
Armenian Saro H, Hudson Melissa M, Lindenfeld Lanie, Chen Sitong, Chow Eric J, Colan Steven, Echevarria Meagan, Wong F Lennie, Chen Ming Hui, Bhatia Smita
机构信息
Division of Outcomes Research, City of Hope, Duarte, California, USA.
Department of Pediatrics, City of Hope, Duarte, California, USA.
出版信息
JACC CardioOncol. 2024 Sep 17;6(5):791-793. doi: 10.1016/j.jaccao.2024.07.015. eCollection 2024 Oct.
Abstract
摘要
相似文献
1
Carvedilol to Improve Cardiac Remodeling in Anthracycline-Exposed Childhood Cancer Survivors: Subgroup Analysis of COG ALTE1621.卡维地洛改善蒽环类药物暴露的儿童癌症幸存者的心脏重塑：儿童肿瘤协作组ALTE1621研究的亚组分析
JACC CardioOncol. 2024 Sep 17;6(5):791-793. doi: 10.1016/j.jaccao.2024.07.015. eCollection 2024 Oct.
2
Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.儿童肿瘤协作组（COG）研究ALTE1621的原理与设计：一项随机、安慰剂对照试验，旨在确定低剂量卡维地洛能否预防有发生心力衰竭高风险的儿童癌症幸存者出现蒽环类药物相关的左心室重塑。
BMC Cardiovasc Disord. 2016 Oct 4;16(1):187. doi: 10.1186/s12872-016-0364-6.
3
Altered Peripheral Blood Gene Expression in Childhood Cancer Survivors With Anthracycline-Induced Cardiomyopathy - A COG-ALTE03N1 Report.癌症患儿蒽环类药物诱导性心肌病患者外周血基因表达谱改变：COG-ALTE03N1 报告
J Am Heart Assoc. 2023 Oct 3;12(19):e029954. doi: 10.1161/JAHA.123.029954. Epub 2023 Sep 26.
4
Add-on multidrug treatment based on quadruple therapy successfully treated worsening heart failure caused by anthracycline-induced cardiomyopathy in a survivor of cancer as a young adult: a case report.附加多药物治疗基于四联疗法成功治疗了年轻癌症幸存者因蒽环类药物诱导性心肌病导致的心力衰竭恶化：病例报告。
BMC Cardiovasc Disord. 2024 Sep 20;24(1):505. doi: 10.1186/s12872-024-04189-z.
5
Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.儿童癌症治疗期间及治疗后用于治疗蒽环类药物引起的有症状和无症状心脏毒性的医学干预措施。
Cochrane Database Syst Rev. 2011 Sep 7(9):CD008011. doi: 10.1002/14651858.CD008011.pub2.
6
Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.儿童癌症治疗期间及治疗后用于治疗蒽环类药物引起的有症状和无症状心脏毒性的医学干预措施。
Cochrane Database Syst Rev. 2016 Aug 23;2016(8):CD008011. doi: 10.1002/14651858.CD008011.pub3.
7
Predicting the 10-year risk of cardiomyopathy in long-term survivors of childhood cancer.预测儿童癌症长期幸存者患心肌病的10年风险。
Ann Oncol. 2025 Jun 4. doi: 10.1016/j.annonc.2025.05.539.
8
Alternative mRNA splicing in anthracycline-induced cardiomyopathy - a COG-ALTE03N1 report.蒽环类药物诱导的心肌病中的可变mRNA剪接——COG-ALTE03N1报告
Cardiooncology. 2025 May 17;11(1):47. doi: 10.1186/s40959-025-00345-2.
9
Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial.卡维地洛对比安慰剂对蒽环类药物暴露的儿童期癌症幸存者心功能的影响（PREVENT-HF）：一项随机、对照、2b 期试验。
Lancet Oncol. 2024 Feb;25(2):235-245. doi: 10.1016/S1470-2045(23)00637-X. Epub 2024 Jan 9.
10
Effects of carvedilol on the prevention of cardiotoxicity induced by anthracyclines: Design and rationale of the CARDIOTOX trial.卡维地洛对预防蒽环类药物所致心脏毒性的作用：CARDIOTOX试验的设计与原理
Am Heart J. 2025 Jul;285:1-11. doi: 10.1016/j.ahj.2025.02.014. Epub 2025 Feb 22.
引用本文的文献
1
Management of late toxicities and specific follow-up needs of adolescent and young adult cancer survivors: recommendations from scientific societies in Spain.青少年和青年癌症幸存者晚期毒性的管理及特定随访需求：西班牙科学协会的建议
Clin Transl Oncol. 2025 Sep 4. doi: 10.1007/s12094-025-04047-0.
本文引用的文献
1
Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial.卡维地洛对比安慰剂对蒽环类药物暴露的儿童期癌症幸存者心功能的影响（PREVENT-HF）：一项随机、对照、2b 期试验。
Lancet Oncol. 2024 Feb;25(2):235-245. doi: 10.1016/S1470-2045(23)00637-X. Epub 2024 Jan 9.
2
Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy.心脏毒性治疗的儿童癌症幸存者应用整体纵向应变和 N 末端 pro-B 型利钠肽改善心肌病风险预测
J Clin Oncol. 2024 Apr 10;42(11):1265-1277. doi: 10.1200/JCO.23.01796. Epub 2024 Jan 11.
3
Cardiac biomarkers and association with subsequent cardiomyopathy and mortality among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort.成人生存的儿童癌症患者中心脏生物标志物与随后发生的心肌病和死亡率的相关性：来自圣裘德终身队列的报告。
Cancer. 2021 Feb 1;127(3):458-466. doi: 10.1002/cncr.33292. Epub 2020 Oct 27.
4
Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association.接受癌症治疗的儿童、青少年和年轻成年人的长期心血管毒性：病理生理学、病程、监测、管理、预防及研究方向：美国心脏协会的科学声明
Circulation. 2013 Oct 22;128(17):1927-95. doi: 10.1161/CIR.0b013e3182a88099. Epub 2013 Sep 30.
Zotero 插件